HMGB1 Is a Therapeutic Target and Biomarker in Diazepam-Refractory Status Epilepticus with Wide Time Window

Overview

Journal Neurotherapeutics

Specialty Neurology

Date 2019 Dec 6

PMID 31802434

Citations 20

Authors

Junli Zhao

Yang Zheng

Keyue Liu

Junzi Chen

Nanxi Lai

Fan Fei

Jiaying Shi

Cenglin Xu

Shuang Wang

Masahiro Nishibori

Yi Wang

Zhong Chen

Affiliations

Soon will be listed here.

Abstract

Status epilepticus (SE), a life-threatening neurologic emergency, is often poorly controlled by the current pharmacological therapeutics, which are limited to a narrow time window. Here, we investigated the proinflammatory cytokine high mobility group box-1 (HMGB1) as a candidate therapeutic target for diazepam (DZP)-refractory SE. We found that HMGB1 was upregulated and translocated rapidly during refractory SE period. Exogenous HMGB1 was sufficient to directly induce DZP-refractory SE in nonrefractory SE. Neutralization of HMGB1 with an anti-HMGB1 monoclonal antibody decreased the incidence of SE and alleviated the severity of seizure activity in DZP-refractory SE, which was mediated by a Toll-like receptor 4 (TLR4)-dependent pathway. Importantly, anti-HMGB1 mAb reversed DZP-refractory SE with a wide time window, extending the therapeutic window from 30 to 180 min. Furthermore, we found the upregulation of plasma HMGB1 level is closely correlated with the therapeutic response of anti-HMGB1 mAb in DZP-refractory SE. All these results indicated that HMGB1 is a potential therapeutic target and a useful predictive biomarker in DZP-refractory SE.

Citing Articles

Prediction of Pharmacoresistance in Drug-Naïve Temporal Lobe Epilepsy Using Ictal EEGs Based on Convolutional Neural Network.

Gong Y, Zhang Z, Yang Y, Zhang S, Zheng R, Li X Neurosci Bull. 2025; .

PMID: 39869168 DOI: 10.1007/s12264-025-01350-2.

Early Polytherapy for Probably Benzodiazepine Refractory Naïve Status Epilepticus (Stage 1 Plus).

Magro G Neurol Int. 2025; 17(1).

PMID: 39852775 PMC: 11767287. DOI: 10.3390/neurolint17010011.

Circuit Reorganization of Subicular Cell-Type-Specific Interneurons in Temporal Lobe Epilepsy.

Fei F, Wang X, Fan X, Gong Y, Yang L, Wang Y J Neurosci. 2024; 45(5).

PMID: 39658255 PMC: 11780357. DOI: 10.1523/JNEUROSCI.0760-24.2024.

CRISPR/Cas9-mediated neuronal deletion of 5-lipoxygenase alleviates deficits in mouse models of epilepsy.

Guan Q, Wang Z, Zhang K, Liu Z, Zhou H, Cao D J Adv Res. 2024; 63:73-90.

PMID: 39048074 PMC: 11379977. DOI: 10.1016/j.jare.2024.07.018.

The effect of the HMGB1/RAGE/TLR4/NF-κB signalling pathway in patients with idiopathic epilepsy and its relationship with toxoplasmosis.

Soyturk H, Onal C, Kilic U, Turkoglu S, Ayaz E J Cell Mol Med. 2024; 28(14):e18542.

PMID: 39046369 PMC: 11267981. DOI: 10.1111/jcmm.18542.

References

Betjemann J, Lowenstein D . Status epilepticus in adults. Lancet Neurol. 2015; 14(6):615-24. DOI: 10.1016/S1474-4422(15)00042-3. View

Shorvon S, Ferlisi M . The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011; 134(Pt 10):2802-18. DOI: 10.1093/brain/awr215. View

Shorvon S . The treatment of status epilepticus. Curr Opin Neurol. 2011; 24(2):165-70. DOI: 10.1097/WCO.0b013e3283446f31. View

Trinka E, Cock H, Hesdorffer D, Rossetti A, Scheffer I, Shinnar S . A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015; 56(10):1515-23. DOI: 10.1111/epi.13121. View

Chen J, Wasterlain C . Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006; 5(3):246-56. DOI: 10.1016/S1474-4422(06)70374-X. View

Wasterlain C, Chen J . Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs. Epilepsia. 2008; 49 Suppl 9:63-73. DOI: 10.1111/j.1528-1167.2008.01928.x. View

Brophy G, Bell R, Claassen J, Alldredge B, Bleck T, Glauser T . Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012; 17(1):3-23. DOI: 10.1007/s12028-012-9695-z. View

Power K, Gramstad A, Gilhus N, Hufthammer K, Engelsen B . Cognitive dysfunction after generalized tonic-clonic status epilepticus in adults. Acta Neurol Scand. 2018; 137(4):417-424. DOI: 10.1111/ane.12898. View

Sutter R, Semmlack S, Kaplan P . Nonconvulsive status epilepticus in adults - insights into the invisible. Nat Rev Neurol. 2016; 12(5):281-93. DOI: 10.1038/nrneurol.2016.45. View

10.

Neligan A, Shorvon S . Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review. Arch Neurol. 2010; 67(8):931-40. DOI: 10.1001/archneurol.2010.169. View

11.

Sutter R, Marsch S, Fuhr P, Kaplan P, Ruegg S . Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2013; 82(8):656-64. PMC: 3945664. DOI: 10.1212/WNL.0000000000000009. View

12.

Santamarina E, Gonzalez-Cuevas G, Sanchez A, Gracia R, Porta I, Toledo M . Prognosis of status epilepticus in patients requiring intravenous anesthetic drugs (a single center experience). Seizure. 2016; 45:74-79. DOI: 10.1016/j.seizure.2016.12.001. View

13.

Novy J, Logroscino G, Rossetti A . Refractory status epilepticus: a prospective observational study. Epilepsia. 2009; 51(2):251-6. DOI: 10.1111/j.1528-1167.2009.02323.x. View

14.

Gorter J, van Vliet E, Aronica E . Status epilepticus, blood-brain barrier disruption, inflammation, and epileptogenesis. Epilepsy Behav. 2015; 49:13-6. DOI: 10.1016/j.yebeh.2015.04.047. View

15.

Janigro D, Iffland 2nd P, Marchi N, Granata T . A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches. Epilepsia. 2013; 54 Suppl 6:30-2. PMC: 4061983. DOI: 10.1111/epi.12271. View

16.

Vezzani A, Granata T . Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia. 2005; 46(11):1724-43. DOI: 10.1111/j.1528-1167.2005.00298.x. View

17.

Lotze M, Tracey K . High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005; 5(4):331-42. DOI: 10.1038/nri1594. View

18.

Zurolo E, Iyer A, Maroso M, Carbonell C, Anink J, Ravizza T . Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. Brain. 2011; 134(Pt 4):1015-32. DOI: 10.1093/brain/awr032. View

19.

Scaffidi P, Misteli T, Bianchi M . Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002; 418(6894):191-5. DOI: 10.1038/nature00858. View

20.

Iori V, Maroso M, Rizzi M, Iyer A, Vertemara R, Carli M . Receptor for Advanced Glycation Endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures. Neurobiol Dis. 2013; 58:102-14. DOI: 10.1016/j.nbd.2013.03.006. View